61 completed, 15 unknown, 13 recruiting, 7 withdrawn. 112 Phase 2, 20 Phase 1, 15 Phase 3.
Follow Vaginal Diseases: new trials by email Literature Review of Vaginal Diseases trials Research Report on Vaginal Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| WST03 Capsule Combined With Metronidazole for Bacterial Vaginosis High-dose WST03 Vaginal Capsule Metronidazole, Low-dose WST03 Vaginal Capsule Metronidazole, Placebo Vaginal Capsule Metronidazole - Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | SPH Sine Pharmaceutical Laboratories Co., Ltd. | 150 | 2026-10-20 | 2026-10-22 |
| MOTIF@FRESH: Modifying Organisms Transvaginally in Females @ FRESH Vaginal Microbiome Transplantation (VMT), oral metronidazole, Sterile saline solution - Recurrent Bacterial Vaginosis (BV) | Phase 2 | Not yet recruiting | Douglas Kwon | 75 | 2026-09-01 | 2026-05-18 |
| A Single-arm, Multicenter Clinical Study of Becotatug Vedotin Combined With Zimberelimab in the Treatment of Recurrent and Metastatic Cervical Cancer, Vulvar Cancer and Vaginal Cancer Becotatug Vedotin in combination with Zimberelimab - Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 30 | 2026-06-11 | 2026-06-16 |
| Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence OCF001 Intravaginal Gel, Placebo Gel - Candidiasis, Vulvovaginal | Phase 2 | Recruiting | Sano Chemicals Inc | 36 | 2026-06-04 | 2026-06-15 |
| Efficacy and Safety Study of BPR-101 Capsules in Combination With Metronidazole in BV Patients BPR-101 capsules:Investigational product for the treatment of BV, Placebo：matching the investigational product in appearance, dosage form, and route of administration - Bacterial Vaginosis | Phase 2 | Not yet recruiting | Chengdu Syncor Pharmaceutical Co., Ltd. | 80 | 2026-04-15 | 2026-03-19 |
| Study to Evaluate Efficacy and Safety of Gyntima® Balance in Preventing Recurrences of Bacterial Vaginosis Lactobacillus gasseri KABP®064 10e9 CFU/capsule, Placebo (maltodextrin) - Vaginosis, Bacterial, Bacterial Vaginosis | Phase 2 / Phase 3 | Not yet recruiting | Kaneka Americas Holding Inc. | 160 | 2026-04-01 | 2026-04-14 |
| Chlorhexidine and/or Metronidazole Plus FB301 Pre-treatment Trial FB 301, Chlorhexidine 0.5%, metronidazole 500 mg - Bacterial Vaginosis (BV) | Phase 2 | Recruiting | Freya Biosciences ApS | 120 | 2026-03-23 | 2026-08-06 |
| Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal Cancer Biospecimen Collection, Prasterone, Survey Administration - Anal Carcinoma, Cervical Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 25 | 2026-03-12 | 2026-04-21 |
| E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers E7 TCR-T cells, Aldesleukin - HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma | Phase 1 / Phase 2 | Recruiting | Christian Hinrichs | 15 | 2025-08-11 | 2026-10-28 |
| A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients WXSH0102/placebo, fluconazole capsules/placebo - Vaginitis | Phase 2 | Recruiting | Cisen Pharmaceutical CO., LTD. | 108 | 2025-01-13 | 2025-02-13 |
| Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin Belzutifan - Ovarian Cancer, Ovarian Carcinoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 32 | 2024-12-20 | 2025-11-05 |
| Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma SCG142, Cyclophosphamide, Fludarabine - HPV-Related Squamous Cell Carcinoma, HPV-Related Cervical Squamous Cell Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | SCG Cell Therapy Pte. Ltd. | 66 | 2024-10-01 | 2024-07-17 |
| HPV Vaccine, Imiquimod, and Metformin Combination Trial HPV vaccine, Imiquimod, and metformin combination therapy - Cervical Carcinoma, Vaginal Carcinoma | Phase 2 | Recruiting | Baylor College of Medicine | 85 | 2024-08-23 | 2024-11-13 |
| Agnostic Therapy in Rare Solid Tumors Nivolumab - Urachal Cancer, Parathyroid Carcinoma | Phase 2 | Active not recruiting | Instituto do Cancer do Estado de São Paulo | 28 | 2024-07-16 | 2026-10-13 |
| Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection BGY-1601-VT, PLACEBO - Bacterial Vaginosis, Vulvovaginal Candidiasis | Phase 1 / Phase 2 | Unknown | NEXBIOME THERAPEUTICS | 165 | 2024-07-08 | 2024-06-12 |
| Postbiotic as Adjunct Treatment for Vaginal Candidiasis Postbiotic, Placebo - Vaginal Candidiasis | Phase 2 / Phase 3 | Completed | Min-Tze LIONG | 99 | 2024-06-02 | 2026-07-07 |
| A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors INCB099280, axitinib - Advanced Solid Tumors | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 5 | 2024-04-16 | 2026-06-04 |
| A Phase II, Single-arm, Multicenter, Prospective Study of Cardunolizumab in Recurrent or Metastatic Vulvar and Vaginal Cancer Cardunolizumab - Vulvar and Vaginal Cancer | Phase 2 | Recruiting | Zhejiang Cancer Hospital | 40 | 2024-03-22 | 2024-11-21 |
| Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis Clotrimazole+Lactulose., Canesten (Clotrimazole), Lactulose - Candidal Vulvovaginitis (ICD-10 Code: B37.3), Vulvovaginal Candidiasis (VVC) | Phase 2 / Phase 3 | Recruiting | AVVA Pharmaceuticals Ltd. | 264 | 2024-02-29 | 2025-02-19 |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Dostarlimab, Bevacizumab, Doxorubicin - Ovarian Neoplasms, Endometrial Neoplasms | Phase 2 | Active not recruiting | Yonsei University | 198 | 2024-01-22 | 2026-11-02 |
Showing 20 of 112. Sign in to see all of them.
Vaginosis, Bacterial (38) · Vaginal Neoplasms (35) · Uterine Cervical Neoplasms (33) · Vulvar Neoplasms (28) · Candidiasis, Vulvovaginal (23) · Endometrial Neoplasms (12) · Vaginitis (12) · Anus Neoplasms (11) · Ovarian Neoplasms (10) · Penile Neoplasms (9) · Oropharyngeal Neoplasms (7) · Carcinoma, Ovarian Epithelial (6) · Fallopian Tube Neoplasms (6) · Uterine Neoplasms (6)
Female Urogenital Diseases (112) · Female Urogenital Diseases and Pregnancy Complications (112) · Genital Diseases (112) · Genital Diseases, Female (112) · Urogenital Diseases (112) · Infections (66) · Bacterial Infections and Mycoses (60) · Vaginitis (59) · Vulvar Diseases (51) · Bacterial Infections (40) · Neoplasms by Site (36) · Urogenital Neoplasms (35) · Uterine Cervical Diseases (34) · Uterine Diseases (34)
Metronidazole (12) · Fluconazole (8) · Radiotherapy (4) · aldesleukin (4) · Clotrimazole (3) · Cyclophosphamide (3) · fludarabine (3) · fludarabine phosphate (3) · Adoptive Transfer (2) · Benchmarking (2) · Bevacizumab (2) · Imiquimod (2) · Nivolumab (2) · Paclitaxel (2) · TOL-463 (2)
National Cancer Institute (NCI) (5) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Dana-Farber Cancer Institute (3) · Christian Hinrichs (2) · Douglas Kwon (2) · Guangdong Longchuangji Pharmaceutical Co., Ltd. (2) · Karolinska Institutet (2) · M.D. Anderson Cancer Center (2) · Matinas BioPharma Nanotechnologies, Inc. (2) · Merck Sharp & Dohme LLC (2) · Ohio State University Comprehensive Cancer Center (2) · Population Council (2) · ProFem GmbH (2) · Scynexis, Inc. (2) · Starpharma Pty Ltd (2)
United States (56) · China (8) · Canada (5) · South Africa (3) · Spain (3) · United Kingdom (3) · Austria (2) · Brazil (2) · Israel (2) · Kenya (2) · Poland (2) · Russia (2) · South Korea (2) · Sweden (2) · Tanzania (2)
Christian S Hinrichs, MD (2) · David Angulo, MD (2) · Ahinoam Lev-Sagie (1) · Alena Jandourek, MD (1) · Alexander Shoushtari (1) · Allison M Quick, MD (1) · Amal Mohamed Alanwar, MD (1) · Amy Lightner, MD (1) · Andrea R Thurman, MD (1) · Anke Hemmerling, MD, MPH, PhD (1) · Anne Macek, MD (1) · Anthony Fyles, MD (1) · Ashwin Chatwani, MD (1) · Camila MV Moniz, Doctor (1)
PMID 36396498, PMID 11230468, PMID 20644497, PMID 20801446, PMID 21992977, PMID 22105720, PMID 24201015, PMID 24983350, PMID 25823737, PMID 25935783, PMID 26210791, PMID 27412883, PMID 28697102, PMID 29304768, PMID 29474292, PMID 29534874, PMID 29697768, PMID 30184181, PMID 30714987, PMID 30807423, PMID 32402161, PMID 32818963, PMID 33207004, PMID 34555149, PMID 34882500, PMID 35113809, PMID 36185311, PMID 37619252, PMID 39516733, PMID 39710508, PMID 40082377, PMID 40194532, PMID 40206350, PMID 40970688, PMID 41276263, PMID 41845293, PMID 42326018, PMID 42678149
2023 (2), 2009 (1), 2025 (1), P30CA043703 (1), R01AI045468 (1), R01AI170564 (1), R01HD098978 (1), R21CA149675 (1), U01CA062502 (1), U01CA287904 (1), U10CA180821 (1), UG1CA189867 (1)